Company Overview and News
Good day and welcome to the Goodrich Petroleum First Quarter 2018 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there'll be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
GDRRQ GDUEQ GDAOQ GDANQ GDPMQ GDP GDPM GDPAN GDPAQ
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GDPMQ RACE PXD GDAOQ CATO GDRRQ AMC IAC PDCE SM IPXL BKE CCL ESTE BRK.A GDP CLDR GOOGL PNC FCAU BA GDPAN GDPAQ WFCNP LMT FB AIHS RCUS CPE GST-A EGY NOVN RAD BWB GST-B WFC.PRL SLP GST WFC.PRJ LB ETH AXAS ADBE GST.PRA GST.PRB WFC.PRT MYL WFC.PRR WFC.PRQ SELB WFC.PRP RYN WFC.PRO WFC.PRN AAPL CCL AMR WFC.PRY WFC.PRX DAL WFC.PRW BBBY DIS WFC.PRV WFC WFC.WS C GDPM CMCSA COST GDUEQ SIX PGEM BLK GDANQ JPM ZUMZ WRD BYD
Every now and then the elephant in the run stomps and makes a lot of noise. Investors had better pay attention because the problem that everyone hoped would never be voiced now makes the front pages followed by potentially more stock impact.
CRC PTQEP GDPMQ CHKVP SDRPQ CHKDH CHKVZ CHKDG CHKDJ GDAOQ CHKDP CHK.PRD GDRRQ CKRGZ GDPM HKRCP HK.WS SD CHKWZ GDUEQ SDOCQ GDANQ GDP CHK CHK.WI HK GDPAN SDRXP PQ SDRXQ GDPAQ
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET